Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patients with CLL

Pt #	Sex	Age, y	Rai stage	Tx status	IgVH	ZAP70⁺	Del 17P⁺	Complex karyotype	Cytogenetics	CD38
Pt #	Sex	Age, y	Rai stage	Tx status	IgVH	ZAP70⁺	Del 17P⁺	Complex karyotype	Cytogenetics	%	MFI	sAbc
1*	F	74	I	TN	Unmutated	NA	N	N	NA	38.01	313	3528
2*	M	68	IV	R/R	Unmutated	N	N	N	del 11q, del 13q	32.31	253	3548
3*	M	66	III	TN	Unmutated	Y	N	N	del 13q	36.46	270	3801
4	M	65	III	R/R	NA	Y	Y	Y	del 13q, del 2q, loss of 11p	20.98	109	1445
5	M	64	II	TN	NA	N	N	N	del 13q	24.55	208	2818
6*	M	66	I	R/R	Unmutated	Y	N	N	del 13q	98	1184	12 558
7*	F	43	0	TN	Unmutated	Y	N	N	del 13q	37.43	180	3489
8	F	78	0	TN	Mutated	N	N	N	Normal	6.3	59	776
9	F	68	NA	R/R	NA	Y	Y	Y	Normal	10.54	132	954
10*	F	69	I	TN	Unmutated	N	Y	Y	del 11q, del 13q	46.71	568	8317
11	M	42	I	TN	Unmutated	Y	Y	Y	del 13q, del 6q, del 11q	13.39	180	2454
12	M	64	0	TN	Mutated	Y	N	N	del 13q	13.12	182	2511
13	M	53	I	PT	Unmutated	Y	N	N	Normal	28.81	243	3388
14	M	59	I	TN	Mutated	Y	N	N	del 11q	18.11	144	3025
15*	M	71	IV	PT	Unmutated	Y	N	N	del 13q	36.1	270	3801
16*	F	69	I	TN	Unmutated	Y	N	N	del 13q	38.54	347	4142
17*	F	50	I	TN	NA	N	N	N	Normal	45.95	401	5498
18	F	74	0	R/R	Unmutated	NA	N	N	Normal	7.58	127	1011
19	M	66	0	TN	Mutated	NA	N	N	del 13q	15.98	137	2544
20	F	58	0	TN	Mutated	N	N	N	Normal	18.3	50	630
21	M	60	I	TN	NA	N	N	N	trisomy 12	13.99	172	2358
22⁺⁺	M	65	III	R/R	Mutated	NA	N	N	del 13q	37.49	431	NA

Pt #	Sex	Age, y	Rai stage	Tx status	IgVH	ZAP70⁺	Del 17P⁺	Complex karyotype	Cytogenetics	CD38
Pt #	Sex	Age, y	Rai stage	Tx status	IgVH	ZAP70⁺	Del 17P⁺	Complex karyotype	Cytogenetics	%	MFI	sAbc
1*	F	74	I	TN	Unmutated	NA	N	N	NA	38.01	313	3528
2*	M	68	IV	R/R	Unmutated	N	N	N	del 11q, del 13q	32.31	253	3548
3*	M	66	III	TN	Unmutated	Y	N	N	del 13q	36.46	270	3801
4	M	65	III	R/R	NA	Y	Y	Y	del 13q, del 2q, loss of 11p	20.98	109	1445
5	M	64	II	TN	NA	N	N	N	del 13q	24.55	208	2818
6*	M	66	I	R/R	Unmutated	Y	N	N	del 13q	98	1184	12 558
7*	F	43	0	TN	Unmutated	Y	N	N	del 13q	37.43	180	3489
8	F	78	0	TN	Mutated	N	N	N	Normal	6.3	59	776
9	F	68	NA	R/R	NA	Y	Y	Y	Normal	10.54	132	954
10*	F	69	I	TN	Unmutated	N	Y	Y	del 11q, del 13q	46.71	568	8317
11	M	42	I	TN	Unmutated	Y	Y	Y	del 13q, del 6q, del 11q	13.39	180	2454
12	M	64	0	TN	Mutated	Y	N	N	del 13q	13.12	182	2511
13	M	53	I	PT	Unmutated	Y	N	N	Normal	28.81	243	3388
14	M	59	I	TN	Mutated	Y	N	N	del 11q	18.11	144	3025
15*	M	71	IV	PT	Unmutated	Y	N	N	del 13q	36.1	270	3801
16*	F	69	I	TN	Unmutated	Y	N	N	del 13q	38.54	347	4142
17*	F	50	I	TN	NA	N	N	N	Normal	45.95	401	5498
18	F	74	0	R/R	Unmutated	NA	N	N	Normal	7.58	127	1011
19	M	66	0	TN	Mutated	NA	N	N	del 13q	15.98	137	2544
20	F	58	0	TN	Mutated	N	N	N	Normal	18.3	50	630
21	M	60	I	TN	NA	N	N	N	trisomy 12	13.99	172	2358
22⁺⁺	M	65	III	R/R	Mutated	NA	N	N	del 13q	37.49	431	NA

Patient 22: cells used in establishment of CLL-PDX model.

F, female; M, male; NA, not available; PT, previously treated; Pt, patient; R/R, relapsed/refractory; sAbc, surface antibody bound per cell; TN, treatment naive; Tx, treatment.

Patients who were designated as CD38 positive using the standardized clinical definition in which more than 30% of CD19⁺CD5⁺ CLL clones express CD38.

View Large

This Feature Is Available To Subscribers Only